BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • Interviews
  • Business Intelligence
  • Case Studies
Intelligence
  • Business Intelligence
  • Case Studies
  • Lab
  • Membership
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers

  Latest News

AI Drug Developer Insilico Medicine Readies Brain-Penetrant Therapy For Parkinson’s Trials

by Roman Kasianov   •   Aug. 18, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Insilico Medicine reports it has finished IND-enabling work for ISM8969, an oral, blood-brain-barrier-penetrant NLRP3 inhibitor and aims to file an IND in Q4 2025 to start clinical evaluation in Parkinson’s disease. In preclinical MPTP models, the candidate reportedly produced dose-dependent motor gains (with significant effects at 20 mg/kg) with a supportive PK/PD package. Full datasets are not yet public.

#advertisement
AI in Drug Discovery Report 2025

In MPTP mouse models, the company reports dose-responsive improvements on open-field, rotarod, and grip-strength assays, with significant effects at 20 mg/kg, alongside a "balanced" druggability and safety profile.

The compound was nominated as a preclinical candidate in December 2024 and is part of Insilico’s broader effort to apply AI across the drug discovery and development pipeline. The company frames NLRP3 inhibition as a potential disease-modifying approach for Parkinson’s, positioning inflammation as a central driver of neurodegeneration.

"Current treatments often cause adverse effects that limit long-term use and do not address the underlying progression," said co-CEO Feng Ren.

The program targets the NLRP3 inflammasome with an oral small molecule designed to modulate neuroinflammation in a condition where approved therapies are largely symptomatic. The release cites a projection that ~25.2 million people may be living with Parkinson’s by 2050, framing the need for disease-modifying approaches.

Insilico attributes the program to its Pharma.AI stack, which spans target discovery to chemistry and development. According to the company, since 2021 it has nominated 22 development/preclinical candidates, received 10 IND clearances, and completed multiple human clinical trials for two advanced programs. It also reports internal efficiency benchmarks—an average 12-18 months from project start to development-candidate nomination with 60–200 molecules synthesized and tested per program.

The announcement follows a string of milestones for Insilico’s AI-derived pipeline. In June, Nature Medicine published Phase IIa results for rentosertib (ISM001-055), an AI-designed TNIK inhibitor for idiopathic pulmonary fibrosis. The same month, the company closed an oversubscribed Series E financing round at $123 million, backing ongoing clinical development and expansion of its AI and automation infrastructure. This includes the rollout of Supervisor, a bipedal lab robot integrated with Insilico’s PandaOmics target discovery system.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • Business Intelligence
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Lab Access
  • Lab Membership
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.